Publication:
Programmed cell death ligand 1 expression level and prognostic significance in acute myeloid leukemia

dc.contributor.coauthorGeduk, Ayfer
dc.contributor.coauthorMehtap, Ozgur
dc.contributor.coauthorDemirsoy, Esra T.
dc.contributor.coauthorMenguc, Meral U.
dc.contributor.coauthorTarkun, Pinar
dc.contributor.coauthorHacihanefioglu, Abdullah
dc.contributor.coauthorBalci, Sibel
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorBirtaş Ateşoğlu, Elif
dc.contributor.kuprofileDoctor
dc.contributor.yokidN/A
dc.date.accessioned2024-11-10T00:05:14Z
dc.date.issued2022
dc.description.abstractPurpose: We aimed to evaluate the expression level of programmed death ligand-1 (PD-L1) and its effects on prognosis in acute myeloid leukemia. Methods: The flow cytometry was used to detect PD-L1 expression on leukemic cells of 86 de novo acute myeloid leukemia patients with longitudinal follow-up. Results: Median follow-up was 13 (0-73) months. The mean of expression level was 3.22 +/- 0.47 at diagnosis and ranged from 0 to 28%. PD-L1 expression tended to be lower in patients with acute promyelocytic leukemia (2.47 +/- 1.08, p = 0.09) but there was no significant difference between neither diagnostic nor cytogenetic subgroups. There was no difference in PD-L1 levels between the patients who achieved complete remission (3.4 +/- 0.61) and those who did not (2.91 +/- 0.72, p = 0.94). The patients with low PD-L1 at diagnosis (median 25 mo [95% CI; 0-56.7]) had a longer overall survival compared with high PD-L1 (median 13 mo [95% CI; 5.52-25.17], p = 0.079). PD-L1 expression was lower at relapse (2.04 +/- 0.79) compared to initial diagnosis (4.52 +/- 0.93, p = 0.049). The patients who had overall survival longer than 1 year showed lower PD-L1 expression at relapse (0.66 +/- 0.93) compared with who had not (5.06 +/- 4.28, p = 0.052). A negative correlation between CD33 and PD-L1 (r = - 0.303, p = 0.005) was detected. Conclusion: Despite its low expression levels, PD-L1 appears to be a clinically important prognostic factor. The negative correlation determined between PD-L1 and CD33 supports the combination approach of PD-L1 inhibitors and CD33 targeted immunotherapies.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume38
dc.identifier.doi10.1007/s12288-021-01473-2
dc.identifier.eissn0974-0449
dc.identifier.issn0971-4502
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85111385921
dc.identifier.urihttp://dx.doi.org/10.1007/s12288-021-01473-2
dc.identifier.urihttps://hdl.handle.net/20.500.14288/16406
dc.identifier.wos677975300001
dc.keywordsPd-L1
dc.keywordsB7-H1
dc.keywordsCd274
dc.keywordsImmune checkpoint
dc.keywordsFlow cytometry Pd-L1 expression
dc.keywordsB7-H1 Pd-L1
dc.languageEnglish
dc.publisherSpringer India
dc.sourceIndian Journal of Hematology and Blood Transfusion
dc.subjectHematology
dc.titleProgrammed cell death ligand 1 expression level and prognostic significance in acute myeloid leukemia
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-2596-4493
local.contributor.kuauthorBirtaş Ateşoğlu, Elif
local.publication.orgunit2KUH (Koç University Hospital)
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab

Files